- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03797456
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL)
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.
Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 110 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 102206
- Beijing Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women between 18 and 75 years old
- Histologically confirmed marginal zone lymphoma (MZL), and at least one measurable tumor of greater than 1.5 centimeter outside of the spleen
- Subjects with refractory or relapsed MZL who has received at least 1 but no more than 4 prior therapies for MZL
- ECOG performance status of 0-2
- Documented failure to achieve at least partial response (PR) or documented disease progression after response to the most recent treatment regimen
- Subjects who have indications for treatment (threatened end-organ function, bulky disease >5cm, symptoms, steady progression, wish to treat)
Subjects meet the following laboratory parameters:
- Absolute neutrophil count (ANC) ≥ 1.5×109/L Platelet count ≥ 75×109/L, independent of growth factor support within 7 days of the first dose with study drug, Hemoglobin ≥ 75 g/L; ANC ≥ 1.0×109/L, Platelet count ≥ 50×109/L, Hemoglobin ≥ 50 g/L; if bone marrow involvement
- Total bilirubin ≤ 1.5× ULN; AST or ALT ≤ 2× ULN; Creatinine ≤ 1.5× ULN; Amylase ≤ ULN and Lipase ≤ ULN
- International normalized ratio (INR) ≤ 1.5 ULN
- Life expectancy ≥ 3 months
- Able to provide signed written informed consent
Exclusion Criteria:
- History of other active malignancies within 5 years of study entry, unless cured without evidence of relapse or metastasis
- Current or history of lymphoma involved central nervous system
- Prior corticosteroids (at dosages equivalent to prednisone > 20 mg/day) given with anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, radiation therapy, or antibody-based therapies or anti-cancer TCM within 4 weeks of the start of study drug
- Non-hematological toxicity must recover to ≤ Grade 1 from prior anti-cancer therapy (except for alopecia)
Current clinically significant cardiovascular disease including:
- Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) < 50%
- Primary cardiomyopathy
- Clinical significant QTc prolong history or QTc>470ms (female) QTc>450ms (male)
- Uncontrolled hypertension
- Known active bleeding within 2 months of screening or currently taking anticoagulant/antiplatelet drugs
- Urine protein ≥ 2+ and quantitation ≥ 2g/24hours
- History of deep vein thrombosis or pulmonary embolism
- Toxicity must be recovered to ≤ Grade 1 from prior anti-cancer therapy
- Disease significantly affecting gastrointestinal function such as dysphagia, chronic diarrhea, intestinal obstruction, or resection of the stomach
- Prior organ or hematopoietic stem cell transplant
- Major surgery within 6 weeks of screening, except for diagnostic test or vascular access setup
- Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection
- Any history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe lung function impairment
- Prior exposure to a BTK or BCR pathway inhibitor (PI3K or Syk) and BCL-2 inhibitor
- Suitable and ready for allogeneic stem cell transplant
- Inability to comply with study procedures
- Drug abuser or alcoholics
- Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children
- Requires treatment with moderate or strong cytochrome P450 family 3, subfamily A (CYP3A) inhibitors or strong CYP3A inducers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ICP-022
|
ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to 3 years
|
The efficacy measured by overall response rate (ORR) in Part II according to the 2014 International Working Group NHL
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria in Part I
Time Frame: Up to 3 years
|
The safety of ICP-022 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria in Part I
|
Up to 3 years
|
Area under the concentration time curve up to the time "t" (AUC(0-t))
Time Frame: up to 4 weeks
|
Area under the concentration time curve up to the time "t" (AUC(0-t)) of ICP-022 will be measured and calculated with noncompartmental analysis using WinNonlin.
|
up to 4 weeks
|
Maximum plasma drug concentrations (Cmax)
Time Frame: up to 4 weeks
|
Individual plasma concentrations of ICP-022 will be measured and Cmax will be calculated with noncompartmental analysis using WinNonlin.
|
up to 4 weeks
|
Time of maximum plasma drug concentrations (Tmax)
Time Frame: up to 4 weeks
|
Time of maximum plasma drug concentrations (Tmax) of ICP-022 will be recorded.
|
up to 4 weeks
|
Apparent half-life for designated elimination phases (t½)
Time Frame: up to 4 weeks
|
Apparent half-life for designated elimination phases (t½) of ICP-022 will be measured and calculated with noncompartmental analysis using WinNonlin.
|
up to 4 weeks
|
Area under the concentration time curve up to the last data point above LOQ (AUC(last))
Time Frame: up to 4 weeks
|
Area under the concentration time curve up to the last data point above LOQ (AUC(last)) of ICP-022 will be measured and calculated with noncompartmental analysis using WinNonlin.
|
up to 4 weeks
|
Progressioin free survival (PFS)
Time Frame: Up to 3 years
|
Progression free survival (PFS) is defined as the time from registration to the first occurrence of progression or relapse as assessed by the investigator, or death from any cause.
PFS for patients without disease progression, relapse, or death will be censored at the time of the last tumor assessment.
|
Up to 3 years
|
Duration of Response (DR)
Time Frame: Up to 3 years
|
Duration of response as defined as the period from the first response (at least PR) to treatment until evidence of disease progression, relapse or death of any cause.
Patients alive without progression and relapse will be censored at the latest tumor assessment date or the stopping date.
|
Up to 3 years
|
Overall survival (OS)
Time Frame: Up to 3 years
|
Overall survival is defined as the period from the induction registration to death from any cause.
Patients who have not died until the time of the analysis will be censored at their last contact date.
|
Up to 3 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICP-CL-00104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MZL
-
BeiGeneCompletedMarginal Zone Lymphoma | MZLChina, Australia, Italy, France, New Zealand, Czechia, United Kingdom, United States, Korea, Republic of
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.UnknownFollicular Lymphoma(FL) | Marginal Zone Lymphoma(MZL)China
-
Incyte CorporationWithdrawnMarginal Zone Lymphoma (MZL) | Follicular Lymphoma ( FL)
-
Regeneron PharmaceuticalsRecruitingRelapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma (MZL)Korea, Republic of, Australia, Spain, Malaysia, Italy, Poland, United States, Thailand, Turkey, France
-
Royal Marsden NHS Foundation TrustUnknownMantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)United Kingdom
-
HutchmedWithdrawnFollicular Lymphoma | Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma | NHL | DLBCL | Richter Syndrome | CLL/SLL | MCL | MZLUnited States, Spain, Australia, Israel, Italy, Poland, France
-
Hospices Civils de LyonThe Lymphoma Academic Research OrganisationRecruitingMantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Diffuse Large B Lymphoma (DLBCL) | Marginal Zone Lymphoma (MZL) | T-cell Lymphoma (T-NHL) | Hodgkin's Lymphoma (HL) | Burkitt Lymphoma (BL))France
-
GenmabAbbVieRecruitingSmall Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FLUnited States, Singapore, Spain, United Kingdom, Denmark, Australia, Canada, Finland, France, Germany, Italy, Netherlands, Poland, Sweden, Korea, Republic of
-
MingSight Pharmaceuticals, IncShenzhen MingSight Relin Pharmaceutical Co., LtdRecruitingChronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)China
-
MEI Pharma, Inc.RecruitingChronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)United States
Clinical Trials on ICP-022
-
Beijing InnoCare Pharma Tech Co., Ltd.Active, not recruitingMantle Cell LymphomaChina
-
Beijing InnoCare Pharma Tech Co., Ltd.Active, not recruitingPCNSL | Secondary Central Nervous System LymphomaChina
-
Beijing InnoCare Pharma Tech Co., Ltd.Active, not recruiting
-
Beijing InnoCare Pharma Tech Co., Ltd.Recruiting
-
Beijing InnoCare Pharma Tech Co., Ltd.Active, not recruitingWaldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia RefractoryChina
-
Shandong UniversityNot yet recruitingImmune Thrombocytopenia | Bruton's Tyrosine Kinase
-
Beijing InnoCare Pharma Tech Co., Ltd.Completed
-
Innocare Pharma Australia Pty LtdCompletedRheumatoid Arthritis | Systemic Lupus ErythematosusAustralia
-
Beijing InnoCare Pharma Tech Co., Ltd.CompletedSystemic Lupus ErythematosusChina
-
Beijing InnoCare Pharma Tech Co., Ltd.Active, not recruitingPart 1:r/r B-cell Malignancies | Part 2:B-cell MalignanciesUnited States, Poland, Israel, Ukraine